Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease

Movement Disorders

Volumn 27, Issue 10, 2012, Pages 1262-1267

  Lewis, Simon J G ^a   Shine, James M ^a   Duffy, Shantel ^a   Halliday, Glenda ^b   Naismith, Sharon L ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Executive function; Hallucinations; Magnetic resonance spectroscopy; N acetyl aspartate; Parkinson's disease

Indexed keywords

CREATINE; N ACETYLASPARTIC ACID;

ADULT; AGED; ANTERIOR CINGULATE; ARTICLE; ATTENTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXECUTIVE FUNCTION; FEMALE; HAMILTON SCALE; HIPPOCAMPUS; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPSYCHIATRY; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL HALLUCINATION;

AGED; ASPARTIC ACID; CASE-CONTROL STUDIES; COGNITION DISORDERS; CREATINE; FEMALE; GYRUS CINGULI; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MENTAL DISORDERS; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84866276861     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25104     Document Type: Article

References (49)

1. Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245.
2. Kudlicka A, Clare L, Hindle JV. Executive functions in Parkinson's disease: systematic review and meta-analysis. Mov Disord 2011; 26: 2305-2315.
3. Ramírez-Ruiz B, Martí MJ, Tolosa E, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007; 14: 750-756.
4. Imamura K, Wada-Isoe K, Kitayama M, Nakashima K. Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. Acta Neurol Scand 2008; 117: 255-259.
5. Postuma RB, Dagher A. Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cereb Cortex 2006; 16: 1508-1521.
6. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-271.
7. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002; 125: 2431-2445.
8. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, et al. Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry 2010; 81: 650-657.
9. Ibarretxe-Bilbao N, Ramírez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol 2008; 255: 1324-1331.
10. Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B, et al. Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia. Mov Disord 2010; 25: 615-622.
11. Ramírez-Ruiz B, Martí MJ, Tolosa E, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007; 14: 750-756.
12. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations. Neurology 2004; 63: 1409-1416.
13. Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 2009; 132: 2980-2993.
14. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005; 20: 130-140.
15. Hobson JA, Pace-Schott EF. The cognitive neuroscience of sleep: neuronal systems, conciousness and learning. Nat Rev Neurosci 2002; 3: 679-693.
16. Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005; 28: 737-757.
17. Shine JM, Halliday GM, Naismith SL, Lewis SJG. Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord 2011; 26: 2154-2159.
18. Collerton DP, Perry E, McKeith I. When people see things that are not there: a novel Perception and Attention Deficit model of recurrent complex visual hallucinations. Behav Brain Sci 2005; 28: 737-757.
19. Shine JM, Halliday GM, Carlos-Lopez M, Naismith SL, Lewis SJG. Investigating visual misperceptions in Parkinson's disease: a novel behavioural paradigm. Mov Disord 2011; 26: 2154-2159.
20. Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined 31P-MRS and 18FDG-PET study. Brain 2000; 123: 340-352.
21. Camiciloi RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004; 354: 177-180.
22. Griffith HR, Okonkwo OC, O'Brien T, Hollander JA. Reduced brain glutamate in patients with Parkinson's disease. NMR Biomed 2008; 21: 381-387.
23. Weston CSE. Another major function of the anterior cingulate cortex: the representation of requirements. Neurosci Biobehav R 2012; 36: 90-110.
24. Duncan J, Owen AM. Common regions of the human frontal lobe recruited by diverse cognitive demands. Trends Neurosci 2000; 23: 475-483.
25. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102: 355-363.
26. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-2170.
27. American Psychiatric Association. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 4th ed. Washington, DC: American Psychiatric Association; 2000.
28. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
29. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, 2nd ed. Oxford, UK: Oxford University Press; 1998.
30. Naismith SL, Shine JM, Lewis SJG. The specific contributions of set-shifting to freezing of gait in Parkinson's disease. Mov Disord 2010; 25: 1000-1004.
31. Delis D, Kaplan E. Delis-Kaplan Executive Function System. San Antonio, TX: Harcourt Brace & Company; 2001.
32. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading cognitive state of patients for clinician. J Psychiatr Res 1975; 12: 189-198.
33. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
34. Talairach J, Tournoux P, Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging. New York: Thieme; 1987.
35. Provencher SW. Estimation of metabolite concentrations from localized in-vivo proton NMR-spectra. Magnet Reson Med 1993; 30: 672-679.
36. Taylor DL, Davies SE, Obrenovitch TP, et al. Extracellular N-acetylaspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K+. J Neurochem 1994; 62: 2349-2355.
37. Baslow MH. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 2003; 28: 941-953.
38. Mehta V, Namboodiri MA. N-acetylaspartate as an acetyl source in the nervous system. Brain Res Mol Brain Res 1995; 31: 151-157.
39. Chakraborty G, Mekela P, Yahya D, Wu G, Ledeen RW. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem 2001; 78: 736-745.
40. Clark JB. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 1998; 20: 271-276.
41. Tsai G, Coyle JT. N-Acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995; 46: 531-540.
42. Chen JG, Charles HC, Barboriak DP, Doraiswamy PM. Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol Scand Suppl 2000; 176: 20-26.
43. Gallagher DA, Parkkinen L, O'sullivan SS, et al. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain 2011; 134: 3299-3309.
44. Meindl T, Teipel S, Elmouden R, et al. Test-retest reproducibility of the default-mode network in healthy individuals. Hum Brain Mapp 2010; 3: 237-246.
45. Silton RL, Helter W, Towers DN, et al. The time course of activity in dorsolateral prefrontal cortex and anterior cingulate cortex during top-down attentional control. NeuroImage 2010; 50: 1292-1302.
46. Fichtenholtz HM, Dean HL, Dillon DG, et al. Emotion-attention network interactions during a visual oddball task. Brain Res Cogn Brain Res 2004; 20: 67-80.
47. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci 2000; 172: 7-11.
48. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992; 42: 887.
49. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998; 21: 289-295.